Last moves
Peptide Exchange
0molecules on your watchlist

Incretins

Semaglutide

No brand name yet

Novo Nordisk weekly GLP 1 injection, approved for type 2 diabetes and weight management. US claims data link a high starting dose to more early discontinuation.

Semaglutide comes from Novo Nordisk and sits in the Incretins class on the board. Route: weekly injection. Use tracked here: Type 2 diabetes and weight management. It stands at Approved on the board, with 4 news moves logged; the latest is dated 3 Nov 2026.

  1. 05ApprovedHere now
  2. 04FiledApplication submitted to a regulator and under review.
  3. 03Phase 3Large confirmatory trials meant to support a filing.
  4. 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
  5. 01Phase 1First doses in people. Safety, dose range, how the body handles it.
Company
Novo Nordisk
Mechanism
GLP 1 receptor agonist peptide
Given as
weekly injection
Lead use on the board
Type 2 diabetes and weight management
Moves logged
4latest today

Semaglutide news moves

  1. ■ ExplainerHolds APP

    Semaglutide employment study ties Wegovy to longer work hours in Denmark

    An NYU Abu Dhabi working paper finds subsidised Ozempic users in Denmark became more likely to work and employed Wegovy users worked more hours. The job entry effect varies by method, and the tax claims rest on a model.

  2. ■ ExplainerHolds APP

    Semaglutide longevity signals grow in mice and DNA clocks but human proof is missing

    Two 2026 papers report slower DNA aging clocks in an HIV trial and longer median lifespan in old female mice on semaglutide. Neither shows that healthy people will live longer, and the researchers behind them say human trials are still needed.

  3. ■ ExplainerNo stage

    Semaglutide kidney disease evidence leads the GLP 1 class while tirzepatide data stay early

    A new review finds the firmest kidney proof in the GLP-1 class belongs to semaglutide and its FLOW trial. Tirzepatide, obesity without diabetes and dialysis still lean on albuminuria, eGFR slope or post hoc data.

  4. ■ ReadoutHolds APP

    Semaglutide discontinuation rose 25 percent when US patients started on a high dose

    A MarketScan claims study of 48,658 US adults finds that the 14.5 percent who began injectable semaglutide on a high dose had a 25 percent higher risk of stopping early and lower persistence at one year.